Neuland Laboratories Limited
Financial trend (100/100) does the heavy lifting; valuation (6/100) is the drag.
ExpensiveOvervaluedStocksWizard rates Neuland Laboratories Limited a Hold, scoring 45/100 on our blended model. We put fair value near ₹9,521.5; at ₹19,043 that leaves roughly 50% downside, so the stock screens overvalued by 50%. On 63.6x trailing earnings it sits pricier than the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹19,697. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹20,972 implies about 10% upside across 4 analysts. It clears 6 of 12 investability checks, with durability 66, valuation 11 and momentum 86 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹7,617.2. Low-confidence estimate — limited data.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-3.32% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- No data: ROE above 15%
- Pass: Low debt (D/E < 0.5): 0.16x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 136%
- Pass: Earnings growing: 664%
- Fail: Net margin ≥ 10%: 2.3%
- Fail: Current ratio > 1.5: 1.42
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 14.47
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter37.8%
- Institutions27.7%
- Public & other34.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 14.47.
Opportunities
- Earnings growing (664% YoY).
- Revenue growing (136% YoY).
Bear case
Weaknesses
- Weak Piotroski score (3/9).
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Neuland Laboratories Limited
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients across India, Europe, the United States, and other markets. The company also offers custom manufacturing solutions and peptide synthesis services. Founded in 1984, it is based in Hyderabad, India.
Neuland Laboratories Limited — frequently asked questions
Is Neuland Laboratories Limited a buy, hold or sell?
StocksWizard currently rates Neuland Laboratories Limited (NEULANDLAB) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Neuland Laboratories Limited's fair value?
Our blended DCF and relative-valuation model estimates Neuland Laboratories Limited's fair value at about ₹9,521.5, versus a current price of ₹19,043 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Neuland Laboratories Limited financially healthy?
Neuland Laboratories Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Neuland Laboratories Limited's share price performed?
Neuland Laboratories Limited is up 18% over three months, and last traded at ₹19,043. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.